Dear Doctor Letter (Rote-Hand-Brief) on Tredaptive®: Results of a clinical study
2013.01.02
Active substance: niacin, laropiprant
Recommendation not to start new patients on treatment with Tredaptive® as the primary endpoint could not be met in the cardiovascular endpoint study HPS2-THRIVE.
(SPC - available in German only)
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN